Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 54.86B 51.43B 46.95B 88.45B 6,084B 88.73B 610B 238B 3,071B 239B 234B 10,184B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.77B 65.41B 59.71B 112B 7,738B 113B 776B 303B 3,906B 304B 297B 12,952B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation : Allergan plc

Latest news : Allergan plc

Press Releases : Allergan plc

News in other languages : Allergan plc

Managers and Directors : Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/8/20	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
5/8/20	Adriane Brown	Issuer sale	Director	2,916	0.0009%
5/8/20	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	-0.13%	-6.44%	+60.34%	+112.06%	1,047B
JOHNSON & JOHNSON	+0.85%	-0.81%	+51.29%	+63.13%	646B
ABBVIE INC.	-1.03%	-3.58%	+21.43%	+73.10%	451B
ROCHE HOLDING AG	-1.46%	-4.50%	+37.80%	+37.41%	355B
NOVARTIS AG	-0.72%	-2.89%	+22.32%	+36.62%	291B
ASTRAZENECA PLC	-1.19%	-2.21%	+1.53%	+10.79%	252B
AMGEN INC.	-1.05%	-1.57%	+50.30%	+66.55%	234B
NOVO NORDISK A/S	+0.08%	-1.78%	-17.64%	-54.36%	203B
GILEAD SCIENCES, INC.	-2.14%	-0.30%	+28.95%	+86.27%	181B
Average	-0.68%	-2.24%	+28.48%	+47.95%	372.29B
Weighted average by Cap.	-0.46%	-3.37%	+38.17%	+65.00%

	2018	2019
Net sales	15.79B 13.6B 12.76B 11.64B 21.93B 1,509B 22B 151B 59.04B 762B 59.27B 57.98B 2,526B	16.09B 13.86B 13B 11.87B 22.35B 1,538B 22.42B 154B 60.17B 776B 60.41B 59.09B 2,574B
Net income	-5.1B -4.39B -4.12B -3.76B -7.08B -487B -7.1B -48.85B -19.06B -246B -19.13B -18.72B -815B	-5.27B -4.54B -4.26B -3.89B -7.32B -504B -7.35B -50.52B -19.71B -254B -19.79B -19.36B -843B
Net Debt	21.89B 18.86B 17.69B 16.14B 30.41B 2,092B 30.51B 210B 81.87B 1,056B 82.19B 80.4B 3,502B	17.3B 14.91B 13.98B 12.76B 24.04B 1,654B 24.12B 166B 64.72B 835B 64.97B 63.56B 2,768B